Popular Trials
Behavioral Nudge for Genetic Predisposition
This trial aims to find new ways to deliver genetic testing results that can change medical management beyond traditional genetic counseling visits. The study will use non-geneticist clinicians and patient nudges in a randomized clinical
Device
Deep Brain Stimulation for Frontotemporal Dementia
This trial is testing a brain implant that sends electrical signals to help people with a specific type of dementia that causes severe symptoms like apathy. The goal is to see if this treatment can improve their brain function and reduce symptoms.
Popular Filters
Trials for FTD Patients
Virus Therapy
PR006 for Frontotemporal Dementia
This trial is testing a new drug called LY3884963 to help people with a specific type of dementia. The drug is given directly to the brain to increase a protein that could improve their condition. The study focuses on patients with genetic mutations that affect their response to usual treatments.
Biguanide
Metformin for ALS
This trial is testing if Metformin, a diabetes drug, is safe and effective for patients with C9orf72 ALS. The drug aims to block harmful proteins linked to their genetic mutation. Metformin has been used to treat type 2 diabetes for more than 60 years and is currently being investigated for its potential anticancer effects.
Hormone Therapy
Oxytocin Nasal Spray for Frontotemporal Dementia
This trial is testing the safety and effects of oxytocin given as a nasal spray to people with frontotemporal dementia or Pick's disease, compared to a placebo. Approximately 112 patients will be enrolled at 15 centers in the US and Canada, and will be given either oxytocin or the placebo nasal spray. The trial will happen in two phases, first testing different doses of oxytocin to see which is most effective, and then randomly assigning patients in the second phase to either the most effective dose of oxytocin or the placebo.
Trials for Primary Progressive Aphasia Patients
Behavioural Intervention
tDCS + Language Therapy for Primary Progressive Aphasia
This trial uses a gentle electrical current applied to the scalp to help patients with Primary Progressive Aphasia improve their language abilities. The treatment stimulates specific brain areas, helping the brain reorganize around damaged regions. This method has shown promise in improving language symptoms in patients with primary progressive aphasia and post-stroke aphasia.
Device
HD-tDCS + mCILT for Primary Progressive Aphasia
This trial is testing whether high-definition transcranial direct current stimulation (HD-tDCS) paired with modified constraint-induced language therapy (mCILT) can improve language performance in people with primary progressive aphasia (PPA). The study will compare changes in language performance and brain imaging before and after receiving 10 semi-consecutive daily sessions of real or sham HD-tDCS + mCILT. The 3-month follow-up will be the primary endpoint.
Tau PET Imaging for Frontotemporal Dementia
This trial uses a drug called AV-1451 to study its ability to bind to tau proteins in the brains of patients with PPA and FTD. By doing this, researchers hope to better understand tau buildup in these conditions.
Trials With No Placebo
Virus Therapy
PR006 for Frontotemporal Dementia
This trial is testing a new drug called LY3884963 to help people with a specific type of dementia. The drug is given directly to the brain to increase a protein that could improve their condition. The study focuses on patients with genetic mutations that affect their response to usual treatments.
Biguanide
Metformin for ALS
This trial is testing if Metformin, a diabetes drug, is safe and effective for patients with C9orf72 ALS. The drug aims to block harmful proteins linked to their genetic mutation. Metformin has been used to treat type 2 diabetes for more than 60 years and is currently being investigated for its potential anticancer effects.
Hormone Therapy
Oxytocin Nasal Spray for Frontotemporal Dementia
This trial is testing the safety and effects of oxytocin given as a nasal spray to people with frontotemporal dementia or Pick's disease, compared to a placebo. Approximately 112 patients will be enrolled at 15 centers in the US and Canada, and will be given either oxytocin or the placebo nasal spray. The trial will happen in two phases, first testing different doses of oxytocin to see which is most effective, and then randomly assigning patients in the second phase to either the most effective dose of oxytocin or the placebo.
Retinal Imaging for Neurodegenerative Disease
This trial uses special cameras to take detailed pictures of the back of the eye in people with cognitive impairments or neurodegenerative diseases. Researchers analyze these images to find early signs of these diseases by examining tiny blood vessels in the eye.
View More Related Trials
Frequently Asked Questions
Introduction to semantic dementia
What are the top hospitals conducting semantic dementia research?
When it comes to the challenging realm of semantic dementia, several top hospitals are taking remarkable strides in clinical trials. In Philadelphia, the University of Pennsylvania is leading the charge with seven ongoing trials focused specifically on this condition. Their dedication to understanding semantic dementia extends back to 2003 when they conducted their first recorded trial. Meanwhile, at Mayo Clinic in Rochester, researchers are vigorously pursuing knowledge by engaging in six active trials and have previously completed 15 investigations since their inaugural study in 2008.
Boston's Massachusetts General Hospital also stands out for its commitment to tackling semantic dementia with four ongoing clinical trials and a history of ten previous studies dating back only a decade ago to2011 . The renowned Johns Hopkins Hospital in Baltimore is equally invested in advancing our understanding of this complex disorder, currently conducting four active trials while having completed five prior investigations since initiating their first trial backin 2007.
Additionally contributing significant research efforts is the University of California San Francisco (UCSF) where three active clinical trials are underway as part of their mission to combat semantic dementia. Although relatively new compared to other institutions mentioned here; however UCSF has swiftly emerged as a major player through achieving seven all-time experimental endeavors thus far, beginning only recently fromtheir initial trial recording as recent as2014.
These esteemed hospitals not only provide hope for those affected by semantic dementia but also demonstrate an unwavering commitment towards unraveling the mysteries surrounding this neurodegenerative disease. The collective work undertaken at these pioneering medical institutions sets us firmly on course towards potential breakthroughs that may ultimately improve lives around the world impacted by this devastating condition.
Which are the best cities for semantic dementia clinical trials?
When it comes to semantic dementia clinical trials, several cities emerge as leading hubs for research and development. San Francisco, California takes the lead with 11 active trials investigating treatments like AL001, Care Ecosystem, and Cohort 2A - [18F]RP-115 in age-matched controls. Philadelphia, Pennsylvania closely follows with 10 ongoing studies focused on interventions such as AL001, Online training site, and Immediate treatment group with Low-Intensity Prompts. Rochester, Minnesota also plays a significant role in this field with 9 active trials exploring options like AL001 and Pittsburgh Compound B (C-11 PiB). These cities provide individuals affected by semantic dementia access to cutting-edge clinical trials that drive progress in understanding and treating this condition.
Which are the top treatments for semantic dementia being explored in clinical trials?
The search for effective treatments in the realm of semantic dementia is ongoing, with several promising options currently being explored in clinical trials. AL001 stands out as a leading candidate, with two active trials dedicated to investigating its potential benefits. This treatment has gained traction since its introduction in 2018 and has contributed to three all-time clinical trials focused on semantic dementia. Additionally, bilateral subgenual cingulate deep brain stimulation (SGC DBS) and Care Ecosystem are emerging contenders, each with one active trial and one all-time trial specifically targeting semantic dementia since their listing in 2023. These innovative approaches offer hope for individuals grappling with this challenging condition.
What are the most recent clinical trials for semantic dementia?
Exciting progress is being made in the realm of semantic dementia with recent clinical trials offering new insights and potential treatments. One such trial focuses on remotely supervised transcranial direct current stimulation (tdcs) paired with word-naming practice for individuals experiencing semantic dementia. This Phase 2 study, which became available on 11/1/2022, explores the efficacy of this intervention in improving language abilities and cognitive function. Additionally, a Phase 3 trial investigates the use of N-Acetyl-L-Leucine as a possible treatment for semantic dementia, aiming to assess its impact on disease progression and symptom management. Lastly, a Phase 1 trial conducted on Verdiperstat examines the safety profile and tolerability of this drug in patients with semantic dementia. These ongoing studies offer hope for improved understanding and potential therapies for those affected by this condition.
What semantic dementia clinical trials were recently completed?
Columbia University recently completed a clinical trial in January 2017, investigating the potential of Lithium Carbonate as a treatment for semantic dementia. This study marks an important step forward in understanding and addressing this debilitating condition.